Detection and Partial Characterization of an Inhibitor of Plasminogen Activator in Human Platelets

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1984 Oct 1

PMID 6434594

Citations 50

Authors

L A Erickson

M H Ginsberg

D J Loskutoff

Affiliations

Soon will be listed here.

Abstract

In this study, we demonstrate the presence of a previously undescribed fibrinolytic inhibitor in human serum. It has an apparent molecular weight of 50,000 and is not detected in serum derived from platelet-poor plasma, suggesting that it originates from platelets. This conclusion is supported by a number of observations. For example, extracts of washed, gel-filtered human platelets contain an inhibitor of similar activity and size, and physiological concentrations of thrombin induce its release from the platelets. Moreover, the kinetics and dose dependency of this release are similar to those observed for the release of platelet factor 4, and the release of both molecules is blocked by pretreating the platelets with prostaglandin E1 and theophylline. Mixing experiments, which were devised to investigate the specificity of the inhibitor, showed that the fibrinolytic activity initiated by both urokinase and tissue-type plasminogen activator was blocked by platelet releasate in a dose-dependent manner. In both cases, the amount of inhibition increased when the releasates were preincubated with the purified activators, indicating a direct interaction between the activators and an inhibitor(s). The inhibitory activity was removed by preincubating the releasates with antiserum prepared against an antiactivator purified from cultured bovine aortic endothelial cells. These results indicate that platelets contain an inhibitor which is released by thrombin, inhibits both urokinase and tissue-type plasminogen activator, and is immunologically similar to an inhibitor produced by endothelial cells. This molecule may represent a new class of inhibitors, the antiactivators, which function together with alpha 2-antiplasmin to regulate the fibrinolytic system of the blood. Its release from platelets by thrombin may protect the growing thrombus against premature dissolution initiated by plasminogen activators released by the endothelium.

Citing Articles

PAI-1 induction during kidney injury promotes fibrotic epithelial dysfunction via deregulation of klotho, p53, and TGF-β1-receptor signaling.

Gifford C, Lian F, Tang J, Costello A, Goldschmeding R, Samarakoon R FASEB J. 2021; 35(7):e21725.

PMID: 34110636 PMC: 8594377. DOI: 10.1096/fj.202002652RR.

PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target.

Altalhi R, Pechlivani N, Ajjan R Int J Mol Sci. 2021; 22(6).

PMID: 33804680 PMC: 8003717. DOI: 10.3390/ijms22063170.

Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA.

Zhang Q, Lei L, Jing D Oncol Rep. 2020; 44(5):1875-1884.

PMID: 33000256 PMC: 7551184. DOI: 10.3892/or.2020.7770.

Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats.

Noguchi R, Kaji K, Namisaki T, Moriya K, Kawaratani H, Kitade M Mol Med Rep. 2020; 22(4):2948-2956.

PMID: 32945412 PMC: 7453658. DOI: 10.3892/mmr.2020.11360.

Impact of Polytrauma and Acute Respiratory Distress Syndrome on Markers of Fibrinolysis: A Prospective Pilot Study.

Negrin L, Dedeyan M, Plesser S, Hajdu S Front Med (Lausanne). 2020; 7:194.

PMID: 32582720 PMC: 7280477. DOI: 10.3389/fmed.2020.00194.

References

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Deutsch D, MERTZ E . Plasminogen: purification from human plasma by affinity chromatography. Science. 1970; 170(3962):1095-6. DOI: 10.1126/science.170.3962.1095. View

Unkeless J, Tobia A, OSSOWSKI L, Quigley J, Rifkin D, Reich E . An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med. 1973; 137(1):85-111. PMC: 2139356. DOI: 10.1084/jem.137.1.85. View

Walsh P, Gagnatelli G . Platelet antiheparin activity: storage site and release mechanism. Blood. 1974; 44(2):157-68. View

Moore S, Pepper D, Cash J . The isolation and characterisation of a platelet-specific beta-globulin (beta-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets. Biochim Biophys Acta. 1975; 379(2):360-9. DOI: 10.1016/0005-2795(75)90143-9. View

Joist J, Niewiarowski S, Nath N, Mustard J . Platelet antiplasmin: its extrusion during the release reaction, subcellular localization, characterization, and relationship to antiheparin in pig platelets. J Lab Clin Med. 1976; 87(4):659-69. View

van Eijk H, van Noort W . Isolation of rat transferrin using CNBr-activated sepharose 4B. J Clin Chem Clin Biochem. 1976; 14(10):475-8. DOI: 10.1515/cclm.1976.14.1-12.475. View

Loskutoff D, Edgington T . Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A. 1977; 74(9):3903-7. PMC: 431779. DOI: 10.1073/pnas.74.9.3903. View

Wiman B, Collen D . Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem. 1977; 78(1):19-26. DOI: 10.1111/j.1432-1033.1977.tb11709.x. View

10.

Joist J . Platelets and fibrinolysis. Thromb Haemost. 1977; 38(4):955-62. View

11.

Loskutoff D . Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. J Clin Invest. 1979; 64(1):329-32. PMC: 372122. DOI: 10.1172/JCI109457. View

12.

Ginsberg M, Hoskins R, Sigrist P, Painter R . Purification of a heparin-neutralizing protein from rabbit platelets and its homology with human platelet Factor 4. J Biol Chem. 1979; 254(24):12365-71. View

13.

Ginsberg M, Taylor L, Painter R . The mechanism of thrombin-induced platelet factor 4 secretion. Blood. 1980; 55(4):661-8. View

14.

Laskowski Jr M, Kato I . Protein inhibitors of proteinases. Annu Rev Biochem. 1980; 49:593-626. DOI: 10.1146/annurev.bi.49.070180.003113. View

15.

Sandbjerg Hansen M, Clemmensen I . Partial purification and characterization of a new fast-acting plasmin inhibitor from human platelets. Evidence for non-identity with the known plasma proteinase inhibitors. Biochem J. 1980; 187(1):173-80. PMC: 1162505. DOI: 10.1042/bj1870173. View

16.

Baker J, Low D, Simmer R, Cunningham D . Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell. 1980; 21(1):37-45. DOI: 10.1016/0092-8674(80)90112-9. View

17.

Collen D . On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980; 43(2):77-89. View

18.

Rijken D, Wijngaards G, Welbergen J . Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med. 1981; 97(4):477-86. View

19.

Rijken D, Collen D . Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981; 256(13):7035-41. View

20.

Matsuo O, Rijken D, Collen D . Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981; 291(5816):590-1. DOI: 10.1038/291590a0. View